Form 4: Labcorp EVP Granted Stock Options, RSUs

Labcorp Holdings Inc.'s EVP, Chief Marketing Officer, Amy B. Summy, was granted non-qualified stock options and restricted stock units on February 10, 2026.

Summary

• Amy B. Summy, Executive Vice President and Chief Marketing Officer of Labcorp Holdings Inc., reported changes in beneficial ownership.
• On February 10, 2026, Ms. Summy was granted 1,900 non-qualified stock options with an exercise price of $284.50 per share.
• These stock options vest in three equal annual installments, beginning on February 10, 2027, and expire on February 9, 2036.
• Additionally, Ms. Summy was granted 620 Restricted Stock Units (RSUs) on February 10, 2026.
• Each RSU represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
• The Restricted Stock Units vest in three equal annual installments, beginning on February 10, 2027.
• Following these transactions, Ms. Summy beneficially owns 1,900 non-qualified stock options and an aggregate of 1,534 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine but positive development, indicating continued executive alignment with company performance through equity compensation, which is generally favorable for long-term shareholder value.

Positives

• The grants of non-qualified stock options and restricted stock units align executive incentives with shareholder interests, promoting long-term performance.
• Equity compensation is a standard practice for retaining key executives and motivating them to achieve company goals.

Future Outlook

The vesting schedules for the granted stock options and Restricted Stock Units indicate a future increase in Amy B. Summy's beneficial ownership of Labcorp Holdings Inc. common stock, contingent on continued employment and company performance.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options and restricted stock units, are a common and effective form of executive compensation across the healthcare diagnostics and broader corporate sectors. This practice is designed to align the interests of executives with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• Equity compensation packages, including stock options and RSUs, are standard practice for executive retention and motivation across various industries, including healthcare and life sciences.
• The structure of multi-year vesting for these grants is consistent with typical industry benchmarks aimed at fostering long-term commitment and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align executive incentives with shareholder interests, potentially leading to improved long-term company performance.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation philosophy for leadership.

Next Steps

• The non-qualified stock options and Restricted Stock Units will vest in three equal annual installments, beginning on February 10, 2027.

Key Dates

Recommendation

This Form 4 reports routine executive compensation grants and does not contain information that would significantly alter an investment thesis for Labcorp Holdings Inc. It primarily indicates ongoing executive alignment with company performance, which is a neutral to slightly positive factor, but not a catalyst for a strong buy or sell recommendation based solely on this filing.

Keywords

Labcorp Holdings Inc., LH, Form 4, Insider Transaction, Executive Compensation, Stock Options, Restricted Stock Units, Amy B. Summy